Coronavirus

A booster dose of the m-RNA vaccine reduced COVID-19 and the rates of severe illness across adult age groups.

New cohort data from VA medical centers provide more evidence of a correlate between antibody levels and vaccine effectiveness for mRNA vaccines.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

Here is a look at some of the treatment alternatives, which can offer simpler logistics and cost considerations.

Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.

Health officials in Mississippi reported a sharp increase in COVID-19-associated deaths among pregnant women during after the Delta variant became predominant.

The FDA granted an Emergency Use Authorization to Evusheld, AstraZeneca’s long-acting monoclonal antibodies for COVID-19 prevention in high-risk individuals.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

New research reveals that women who test positive for COVID-19 at the time they give birth pass along antibodies in breast milk, protecting their newborns from infection

Parents who were themselves vaccinated against COVID-19 were more likely to vaccinate their children than parents who were not, yet even vaccinated parents showed some hesitancy.

High-titer convalescent plasma administered to high-risk outpatients within a week of symptom onset didn’t prevent disease progression, according to a new study.

The recall involves 2 lots of 100 mg of remdesivir for injection to the user level.

The agency said the 2 monoclonal antibodies could be used to treat mild to moderate COVID-19 in all younger pediatric patients, including newborns.

A new study looked at COVID-19 related stressors and healthcare experiences, like facing discrimination, fear of perinatal infection, birth preparedness stress, telehealth prenatal care, disruptions to prenatal care, birth satisfaction, and duration of hospitalization and how these factors affected vaccination.

Higher ACE2 expression may explain why elderly people experience more severe COVID-19.

A study released tonight found 6 COVID-19 booster shots increased immunity for individuals who received a full 2 doses of the AstraZeneca or Pfizer-BioNTech vaccines.

The strategies address booster doses, travel, and rapid response.

The first Omicron COVID-19 case was discovered in California. The patient, who traveled from South Africa, has since recovered.

If the FDA authorizes molnupiravir based on the Antimicrobial Drugs Advisory Committee's recomendation, it would become the first oral COVID-19 treatment.

A recent study attributed COVID-19 morbidity and mortality disparities to “upstream issues” such as underlying conditions and lack of access to testing and care.

As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.

Moderna and Pfizer's CEOs voice doubt on the current vaccines’ efficacy with the new variant, but are developing prophylaxis vaccines and treatment strategies to curtail the new strain.

While there is much still unknown about the Omicron variant, the World Health Organization says it poses “very high” risk due to its increased transmissibility.

Inhaled ciclesonide did not shorten duration of mild to moderate symptoms of COVID-19 in outpatients, but lessened hospitalizations.

The strain identified as B.1.1.529 is causing some travel restrictions from some African countries, and medical science is rushing to understand its potential impact on the global stage.

COVID-19 vaccines are frequently tested in low- and middle-income countries, but they have experienced significant delays in vaccinating their own populations.

COVID-19 infection during pregnancy induced immune system rewiring in both mothers and their infants.

In its first real-world study, 2 doses of India’s BBV152 vaccine offered 50% protection against symptomatic COVID-19.

Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.

The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.